Scancell Holdings PLC (LSE:SCLP) Share Price

Company Profile

Business description
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
Contact
Sanders Road
Unit 202, Bellhouse Building
Oxford Science Park
OxfordOX4 4GD
GBR
T: +44 1865582066
https://www.scancell.co.uk
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 April 2026
Employees
58

Recommended

Any missteps this reporting season could be costly for these shares, which have all risen to lofty valuations.

Joseph Taylor | 03 August 2025

We were wrong when we thought last quarter would be hard to top.

Dan Romanoff, CPA | 31 July 2025

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,917.10	81.90	-0.91%
CAC 40	7,546.16	225.81	-2.91%
DAX 40	23,425.97	639.50	-2.66%
Dow JONES (US)	43,588.58	542.40	-1.23%
FTSE 100	9,068.58	64.23	-0.70%
HKSE	24,507.81	265.52	-1.07%
NASDAQ	20,650.13	472.31	-2.24%
Nikkei 225	40,799.60	270.22	-0.66%
NZX 50 Index	12,729.40	94.34	-0.74%
S&P 500	6,238.01	101.38	-1.60%
S&P/ASX 200	8,662.00	80.80	-0.92%
SSE Composite Index	3,559.95	13.26	-0.37%